KPV

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH 11-13), a fragment of the anti-inflammatory neuropeptide alpha-MSH. ^{[1] [2]} KPV retains almost all of the anti-inflammatory capacity of the full alpha-MSH hormone while displaying a lack of any pigmentary action. ^[3] Its physicochemical properties and expected low costs of production have made it an interesting candidate for anti-inflammatory peptide therapy for immune-mediated inflammatory skin and bowel diseases, allergic asthma and arthritis. ^{[3] [2]}

Alpha-MSH and its fragment KPV modulate inflammation, and the key to this anti-inflammatory influence is inhibition of the transcription factor NF-kappa B. ^[4] KPV lacks the entire sequence motif required for binding to any of the known melanocortin receptors, yet retains anti-inflammatory activity, and the exact signaling mechanism it uses is currently unknown. ^[3] In tests of antimicrobial activity, alpha-MSH and its fragment KPV showed inhibitory influences against the gram-positive bacterium Staphylococcus aureus and the yeast Candida albicans. ^[5] In host-defense-peptide reviews of inflammatory bowel disease, KPV is described as downregulating the NF-kappa B pathway, modulating cytokine release, and restoring homeostasis. ^[6]

In a mouse model of contact hypersensitivity, systemic and topical application of alpha-MSH or KPV inhibited both the sensitization and the elicitation phase and was able to induce hapten-specific tolerance. ^[1] In wound-healing research, KPV-loaded hydrogels were reported to reduce inflammation, promote tissue regeneration, and combat MRSA infections. ^[7] Reviews frame KPV and related alpha-MSH tripeptides as candidate agents for immune-mediated inflammatory diseases, positioning them as a potential future approach rather than an established therapy. ^{[3] [8]} KPV has also appeared as a synthetic peptide fragment promoted for anti-inflammatory effects in the recreational and bodybuilding market, where it remains an experimental substance with poorly defined long-term risks. ^[9]

By retaining the anti-inflammatory activity of alpha-MSH without its pigmentary effect, KPV addresses one of the major obstacles that has limited the use of alpha-MSH itself in human inflammatory disorders. ^{[2] [3]} The available evidence for KPV is drawn from mechanistic and preclinical work rather than large controlled human trials, and its precise signaling mechanism remains undefined. ^[3]